Abstract
BackgroundUse of immune checkpoint inhibitors (ICI) has revolutionised management of multiple malignancies but may be complicated by development of immune-related adverse events including inflammatory arthritis. Once triggered, arthritis may persist,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
